Astellas Forecasts Earnings Decline; Says Urology Franchise Will Drive Global Growth
This article was originally published in PharmAsia News
Executive Summary
Astellas recently reported declining sales, operating income and profits for fiscal year 2008 due to the appreciation of the yen and the revision of Japan's drug pricing policy. The decline in sales and earnings was the first to be posted since the 2005 merger between Fujisawa and Yamanouchi Pharmaceutical
You may also be interested in...
Astellas To Set Up Branch Office In Chengdu
Japanese drug R&D corporation Astellas, ranked 35th on the Fortune 500 list in 2008, will establish a branch office in Chengdu to handle business in southwest and northwest China. The new office will be in charge of marketing promotion in the western region, along with bringing the world's most updated drug information, healthcare developments and market trends to hospitals and doctors. Depending on the market situation, the firm does not rule out the possibility of setting up a pharmaceutical plant or R&D center in the city. Texas Instruments is another Fortune 500 company setting up a base in Chengdu. (Click here for more - Chinese Language)
Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
Usually, having more money that you know how to use is not considered a problem, but cash-rich Astellas may feel a bit stranded now that Gilead has trumped its bid to buy CV Therapeutics. But at least one analyst thinks the U.S. biotech sector still offers plenty of potential acquisitions for the Japanese pharma
Astellas Advances Antibody R&D Agenda With Agensys Purchase Worth Up To $537 Million
Astellas has agreed to buy Agensys, a privately held U.S. biotech with a portfolio of novel cancer targets and monoclonal antibodies to match, in a deal worth up to $537 million, the firms announced Nov. 27